Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03545711
Recruitment Status : Recruiting
First Posted : June 4, 2018
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Jing Huang, Chinese Academy of Medical Sciences

Brief Summary:
Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of this prospective non-randomised study in an escalated dose cohort. The primary endpoint of the dose-escalation phase is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of anlotinib when given in combination with irinotecan. The phase II (dose-expansion) portion is designed to characterize the safety and potential efficacy of the combination therapy in pretreated advanced colorectal cancer patients.

Condition or disease Intervention/treatment Phase
Colo-rectal Cancer Drug: Anlotinib Hydrochloride with Irinotecan Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Irinotecan Combined With Anlotinib in Patients With Pretreated Advanced Colorectal Cancer
Actual Study Start Date : May 26, 2018
Estimated Primary Completion Date : November 24, 2019
Estimated Study Completion Date : November 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Anlotinib plus Irinotecan Drug: Anlotinib Hydrochloride with Irinotecan
Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.




Primary Outcome Measures :
  1. MTD [ Time Frame: 6 months ]
    the maximum tolerated dose (MTD) of Anlotinib when administered in combination with fixed dose of irinotecan in advanced colorectal cancer patients.

  2. ORR [ Time Frame: 18 months ]
    the overall response rate (ORR) of Anlotinib when administered in combination with fixed dose of irinotecan in advanced colorectal cancer patients.


Secondary Outcome Measures :
  1. DCR [ Time Frame: 18 months ]
    the disease control rate (DCR) of the combination of Anlotinib with Irinotecan in pretreated advanced colorectal cancer patients.

  2. PFS [ Time Frame: 18 months ]
    the progression free survival (PFS) of the combination of Anlotinib with Irinotecan in pretreated advanced colorectal cancer patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  • willing and able to provide written informed consent and comply with the requirements of the study
  • histologically- or cytologically-confirmed advanced colorectal cancer
  • failed or intolerable to at least one prior therapy
  • have evidence of measurable disease per RECIST v1.1
  • Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1
  • weight ≥40kg
  • life expectancy >12 weeks

Exclusion Criteria:

Subjects meeting any of the following criteria are ineligible for participation in the study:

  • history of any anti-cancer therapy (including investigational agents) within 28 days prior to study entry
  • presence of toxicity of prior anti-cancer therapy that has not resolved to Grade 1, as determined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
  • symptomatic brain metastasis requiring active treatment
  • any previous malignancy, except for non squamous-cell carcinoma of skin or carcinoma-in-situ of the uterine cervix within 5 years prior to study entry
  • active or clinically unstable infection requiring systemic therapy
  • unable to swallow oral medications or with gastrointestinal disorders that might interfere with proper absorption of oral drugs
  • active digestive ulcer disease, inflammatory bowel disease, intestinal obstruction or any other condition that, in the clinical judgment of the Principal Investigator, may cause severe gastrointestinal bleeding or perforation
  • unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event ≤2 months prior to study entry
  • history of stroke or transient ischemic attack (TIA) within 12 months prior to study entry
  • any of the following abnormal findings in organ or marrow function 1 week prior to study entry:

    • Leukocytes < 1.5*10^9/L, or Platelets < 100*10^9/L, or Hb< 90g/L
    • Total bilirubin > 1.5 × institutional upper limit of normal (ULN), or AST (aspartate amino transferase)/ALT (alanine amino transferase)> 3 × institutional ULN for liver metastases, > 1.5 × institutional ULN in case of no liver metastases
    • any electrolyte imbalance of clinical significance
    • creatinine > institutional ULN and creatinine clearance < 60 mL/min
    • spot urine protein ≥(2+) or 24-hour proteinuria ≥1.0g/24h
    • APTT (activated partial thromboplastin time) or INR (international normalized ratio for prothrombin time) > 1.5 × institutional ULN
  • treatment refractory hypertension defined as a blood pressure of systolic> 140 millimeter of mercury (mm Hg) and/or diastolic > 90 mm Hg which cannot be controlled by a single anti-hypertensive agent
  • LVEF (left ventricular ejection fraction ) <50%
  • history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary artery bypass graft within 6 months prior to study entry, or history or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association (NYHA)
  • present with non-healing fractures of bone or wounds of skin
  • pregnant or lactating female
  • sexually active female (of childbearing potential) or male unwilling to adopt an effective method of birth control during the course of the study
  • serious and/or unstable pre-existing psychiatric disorder
  • familial, sociological or geographical conditions that, in the clinical judgment of the Principal Investigator, do not permit compliance with the protocol
  • known immediate or delayed hypersensitivity reaction to anlotinib, irinotecan or their excipients
  • administration of irinotecan in prior treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03545711


Contacts
Layout table for location contacts
Contact: Jing Huang, MD 86-10-87788102 huangjingwg@163.com
Contact: Yan Song, M.D

Locations
Layout table for location information
China
Jing Huang Recruiting
Beijing, China, 100021
Contact: Jing Huang, MD         
Sponsors and Collaborators
Chinese Academy of Medical Sciences
Investigators
Layout table for investigator information
Principal Investigator: Jing Huang, MD Cancer Hospital,CAMS

Layout table for additonal information
Responsible Party: Jing Huang, Professor, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT03545711     History of Changes
Other Study ID Numbers: NCC201803012
First Posted: June 4, 2018    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Irinotecan
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents